UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-KSB/A
Amendment No. 1

x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2007

OR

o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM _______________ TO _____________

Commission File No. 1-11140

OPHTHALMIC IMAGING SYSTEMS

(Name of small business issuer in its charter)

California	94-3035367
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
221 Lathrop Way, Suite I, Sacramento, CA	95815
(Address of principal executive offices)	(Zip Code)

Issuer’s telephone number: (916) 646-2020

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act: Common Stock, no par value

Check whether the issuer is not required to file reports pursuant to Section 13 or 15 (d) of the Exchange Act. x

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No o

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

The issuer’s revenues for its most recent fiscal year were $15,130,056.

The aggregate market value of the voting and non-voting common stock of the issuer held by non-affiliates as of March 14, 2008 was approximately $2,684,392based upon the closing price of the common stock as quoted by Nasdaq OTC Bulletin Board on such date.

As of March 14, 2008, there were 16,866,831 issued and outstanding shares of the issuer’s common stock.

Transitional Small Business Disclosure Format (check one): Yes o  No x

Explanatory Note

Ophthalmic Imaging Systems (“we,” “us,” or “our”) is filing this Amendment No. 1 on Form 10-KSB/A (this “Amendment No. 1”) to amend our Annual Report on Form 10-KSB, for the fiscal year ended December 31, 2007, as filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2008 (the “Original Filing”). The purpose of this Amendment No. 1 is to revise the officers’ certifications attached as Exhibits 31.1 and 31.2 to conform with Item 601(b)(31) of Regulation S-B.

Except for the revisions to the officers’ certifications attached as Exhibits 31.1 and 31.2 to conform with Item 601(b)(31) of Regulation S-B, we have not undertaken in this Amendment No. 1 to modify or update any other disclosures in our Original Filing and this Amendment No. 1 does not reflect any events occurring after the date of filing of the Original Filing.

Signatures

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OPHTHALMIC IMAGING SYSTEMS
Dated: July 18, 2008	By:	/s/ Gil Allon
	Name:  Gil Allon
	Title:    Chief Executive Officer (Principal Executive Officer)
	By:	/s/ Ariel Shenhar
	Name:  Ariel Shenhar
	Title:   Chief Financial Officer (Principal Accounting and Financial Officer)

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

/s/ Gil Allon
Gil Allon	Director	July 18, 2008
/s/ Ariel Shenhar
Ariel Shenhar	Director	July 18, 2008
/s/ Yigal Berman
Yigal Berman	Director, Chairman of the Board	July 18, 2008
Jonathan R. Phillips	Director	July 18, 2008
/s/ William Greer
William Greer	Director	July 18, 2008
Marc De Clerck	Director	July 18, 2008